Overview

A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism

Status:
Unknown status

Trial end date:
2014-08-01

Target enrollment:

Participant gender:

Summary

Patients with HCV genotype 1 and IL28B CC Polymorphism who have a rapid virological response to treatment are randomised to either 24 or 48 weeks HCV treatment. Our hypothesis is that there is no important difference in effect between the two treatment effect.

Phase:

Phase 3

Details

Lead Sponsor:

Third Affiliated Hospital, Sun Yat-Sen University

Treatments:

Interferon-alpha
Peginterferon alfa-2a
Ribavirin